Takeda Pharmaceutical Company Limited
Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) ...
mehr